Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 537 | 79350-37-1 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.06 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 41 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 29.33 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 47 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.24 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.31 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 3.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 28, 1989 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 63.75 | 20.26 | 80 | 3229 | 250930 | 50350885 |
Gastroenteritis staphylococcal | 43.67 | 20.26 | 7 | 3302 | 70 | 50601745 |
Secretion discharge | 32.98 | 20.26 | 15 | 3294 | 9776 | 50592039 |
Panic attack | 31.11 | 20.26 | 18 | 3291 | 19324 | 50582491 |
Mucocutaneous candidiasis | 30.15 | 20.26 | 4 | 3305 | 8 | 50601807 |
Pulmonary congestion | 29.44 | 20.26 | 16 | 3293 | 15231 | 50586584 |
Dysbiosis | 28.67 | 20.26 | 7 | 3302 | 653 | 50601162 |
Biopsy colon abnormal | 27.55 | 20.26 | 5 | 3304 | 109 | 50601706 |
Gastrointestinal mucosa hyperaemia | 25.06 | 20.26 | 5 | 3304 | 183 | 50601632 |
Movement disorder | 24.67 | 20.26 | 15 | 3294 | 17617 | 50584198 |
Oligohydramnios | 23.20 | 20.26 | 10 | 3299 | 5740 | 50596075 |
Vaginal infection | 22.42 | 20.26 | 10 | 3299 | 6226 | 50595589 |
Malignant melanoma in situ | 22.33 | 20.26 | 6 | 3303 | 819 | 50600996 |
Candida test positive | 22.05 | 20.26 | 6 | 3303 | 858 | 50600957 |
Foetal growth restriction | 21.84 | 20.26 | 10 | 3299 | 6617 | 50595198 |
Premature baby | 21.63 | 20.26 | 14 | 3295 | 18323 | 50583492 |
Pulmonary mass | 21.38 | 20.26 | 14 | 3295 | 18691 | 50583124 |
Disorientation | 21.23 | 20.26 | 18 | 3291 | 35466 | 50566349 |
Drug reaction with eosinophilia and systemic symptoms | 20.33 | 20.26 | 16 | 3293 | 28408 | 50573407 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Oral pustule | 43.95 | 24.91 | 8 | 1425 | 243 | 29572851 |
Psoriatic arthropathy | 37.75 | 24.91 | 17 | 1416 | 14674 | 29558420 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Secretion discharge | 54.52 | 18.90 | 23 | 4406 | 11941 | 64482362 |
Panic attack | 50.76 | 18.90 | 26 | 4403 | 20927 | 64473376 |
Drug hypersensitivity | 48.54 | 18.90 | 70 | 4359 | 237745 | 64256558 |
Pulmonary congestion | 44.81 | 18.90 | 25 | 4404 | 23855 | 64470448 |
Psoriatic arthropathy | 44.75 | 18.90 | 31 | 4398 | 43250 | 64451053 |
Movement disorder | 41.19 | 18.90 | 23 | 4406 | 21977 | 64472326 |
Oral pustule | 40.33 | 18.90 | 8 | 4421 | 270 | 64494033 |
Pulmonary mass | 39.31 | 18.90 | 23 | 4406 | 23993 | 64470310 |
Clostridium difficile colitis | 39.18 | 18.90 | 24 | 4405 | 27199 | 64467104 |
Gastroenteritis staphylococcal | 34.31 | 18.90 | 7 | 4422 | 273 | 64494030 |
Dysbiosis | 31.02 | 18.90 | 8 | 4421 | 887 | 64493416 |
Biopsy colon abnormal | 27.91 | 18.90 | 5 | 4424 | 96 | 64494207 |
Agranulocytosis | 25.33 | 18.90 | 21 | 4408 | 38208 | 64456095 |
Mucocutaneous candidiasis | 24.76 | 18.90 | 4 | 4425 | 40 | 64494263 |
Acute generalised exanthematous pustulosis | 24.43 | 18.90 | 14 | 4415 | 14044 | 64480259 |
Pseudomembranous colitis | 24.23 | 18.90 | 10 | 4419 | 4906 | 64489397 |
Vaginal infection | 24.23 | 18.90 | 10 | 4419 | 4910 | 64489393 |
Drug reaction with eosinophilia and systemic symptoms | 22.65 | 18.90 | 23 | 4406 | 54194 | 64440109 |
Gastrointestinal mucosa hyperaemia | 20.76 | 18.90 | 5 | 4424 | 419 | 64493884 |
Candida test positive | 20.49 | 18.90 | 6 | 4423 | 1064 | 64493239 |
Psoriasis | 18.98 | 18.90 | 24 | 4405 | 71679 | 64422624 |
None
Source | Code | Description |
---|---|---|
ATC | J01DD08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
ATC | J01RA15 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:88188 | allergenic drug |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute otitis media | indication | 3110003 | |
Gonorrhea | indication | 15628003 | DOID:7551 |
Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
Acute gonococcal urethritis | indication | 29864006 | |
Bronchitis | indication | 32398004 | DOID:6132 |
Streptococcal tonsillitis | indication | 41582007 | |
Upper respiratory infection | indication | 54150009 | |
Urinary tract infectious disease | indication | 68566005 | |
Tonsillitis | indication | 90176007 | DOID:10456 |
Acute bacterial bronchitis | indication | 233598009 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Infective otitis media | indication | 312218008 | |
Pharyngitis | indication | 405737000 | DOID:2275 |
Acute exacerbation of chronic bronchitis | indication | 425748003 | |
Haemophilus Influenzae Acute Otitis Media | indication | ||
Haemophilus Influenzae Chronic Bronchitis | indication | ||
Streptococcus Pneumoniae Chronic Bronchitis | indication | ||
Haemophilus Influenzae Bronchitis | indication | ||
Moraxella Catarrhalis Acute Otitis Media | indication | ||
Streptococcus Pneumoniae Bronchitis | indication | ||
Pneumonia due to Escherichia coli | off-label use | 51530003 | |
Acute bacterial sinusitis | off-label use | 75498004 | |
Haemophilus Parahaemolyticus Pneumonia | off-label use | ||
Haemophilus Parainfluenzae Pneumonia | off-label use | ||
Impaired renal function disorder | contraindication | 197663003 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.45 | acidic |
pKa2 | 2.54 | acidic |
pKa3 | 3.24 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
500MG/5ML | SUPRAX | LUPIN LTD | N202091 | Feb. 20, 2013 | RX | FOR SUSPENSION | ORAL | 9233112 | Dec. 14, 2028 | METHODS FOR TREATING BACTERIAL INFECTIONS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | IC50 | 4.24 | WOMBAT-PK | |||||
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Enzyme | IC50 | 5.92 | CHEMBL | |||||
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Streptokinase A | Enzyme | EC50 | 7.22 | WOMBAT-PK |
ID | Source |
---|---|
4019391 | VUID |
N0000147544 | NUI |
D00258 | KEGG_DRUG |
25033 | RXNORM |
4019391 | VANDF |
C0060400 | UMLSCUI |
CHEBI:472657 | CHEBI |
C04 | PDB_CHEM_ID |
CHEMBL1541 | ChEMBL_ID |
D020682 | MESH_DESCRIPTOR_UI |
DB00671 | DRUGBANK_ID |
10898 | IUPHAR_LIGAND_ID |
97I1C92E55 | UNII |
5362065 | PUBCHEM_CID |
233747 | MMSL |
4374 | MMSL |
d00072 | MMSL |
002737 | NDDF |
387536009 | SNOMEDCT_US |
96052006 | SNOMEDCT_US |
125110-14-7 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-766 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-767 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-201 | TABLET | 400 mg | ORAL | ANDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-203 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 19 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-203 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 19 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-205 | TABLET, CHEWABLE | 200 mg | ORAL | ANDA | 19 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-205 | TABLET, CHEWABLE | 200 mg | ORAL | ANDA | 19 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-206 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-207 | POWDER, FOR SUSPENSION | 500 mg | ORAL | NDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-208 | CAPSULE | 400 mg | ORAL | NDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-673 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 22 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-674 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 22 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54348-797 | CAPSULE | 400 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-663 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-664 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-668 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 27 sections |
Cefixime | Human Prescription Drug Label | 1 | 65862-751 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 25 sections |
Cefixime | Human Prescription Drug Label | 1 | 65862-752 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 25 sections |
CEFIXIME | Human Prescription Drug Label | 1 | 67877-584 | CAPSULE | 400 mg | ORAL | ANDA | 24 sections |
CEFIXIME | Human Prescription Drug Label | 1 | 67877-584 | CAPSULE | 400 mg | ORAL | ANDA | 24 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-202 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
CEFIXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-405 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 25 sections |
CEFIXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-407 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 25 sections |
CEFIXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-416 | CAPSULE | 400 mg | ORAL | ANDA | 25 sections |
CEFIXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-423 | CAPSULE | 400 mg | ORAL | NDA authorized generic | 25 sections |
CEFIXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2749 | CAPSULE | 400 mg | ORAL | ANDA | 24 sections |
CEFIXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-3221 | CAPSULE | 400 mg | ORAL | NDA authorized generic | 25 sections |
CEFIXIME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-3221 | CAPSULE | 400 mg | ORAL | NDA authorized generic | 25 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70934-079 | CAPSULE | 400 mg | ORAL | NDA | 28 sections |